Pfizer (PFE) Net Cash Flow (2009 - 2026)

Pfizer (PFE) has 18 years of Net Cash Flow data on file, last reported at $544.0 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $544.0 million, up 42.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $211.0 million (up 121.4% YoY), and the FY2025 annual result was $49.0 million, up 102.81% from the prior year.
• Net Cash Flow grew to $544.0 million in Q1 2026 per PFE's latest filing, from -$202.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $1.8 billion in Q2 2023 and troughed at -$2.1 billion in Q1 2024.
• A 5-year average of -$66.4 million and a median of $173.0 million in 2025 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow jumped 3412.5% in 2022, then plunged 405.84% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$507.0 million in 2022, then surged by 38.07% to -$314.0 million in 2023, then slumped by 450.32% to -$1.7 billion in 2024, then jumped by 88.31% to -$202.0 million in 2025, then soared by 369.31% to $544.0 million in 2026.
• Business Quant data shows PFE's Net Cash Flow at $544.0 million in Q1 2026, -$202.0 million in Q4 2025, and -$304.0 million in Q3 2025.